Last updated: January 30, 2026
Executive Summary
Fresenius Kabi USA, LLC ("Fresenius") initiated patent infringement litigation against Custopharm, Inc. ("Custopharm") in the U.S. District Court for the Southern District of New York. The case, docketed as 1:20-cv-03254, revolves around alleged infringement of Fresenius’s patent rights related to intravenous drug formulations. The dispute underscores ongoing patent enforcement strategies within the sterile injectable pharmaceutical and drug delivery device markets, notably concerning competitive challenges over formulation patents.
This summary outlines the procedural posture, key patent claims, defense contentions, recent developments, and strategic implications for pharmaceutical patent holders and generic manufacturers.
Case Overview and Procedural Posture
| Date |
Event |
Description |
| April 21, 2020 |
Complaint filed |
Fresenius files patent infringement complaint against Custopharm, asserting violations of U.S. Patent No. 10,057,715 (the “’715 Patent”). |
| June 2020 |
Answer and counterclaims |
Custopharm disputes infringement, asserting invalidity and non-infringement defenses. |
| January 2022 |
Claim Construction |
Court issues a Markman ruling on key claim terms, influencing scope of the patent rights. |
| March 2022 |
Summary Judgments considered |
Parties file motions for summary judgment; disputes focus on patent validity and infringement. |
| June 2022 |
Trial scheduled |
Trial set for Q1 2023, with ongoing discovery and expert disclosures. |
Patents at Issue: Technical Scope and Claims
Patent Number: U.S. Patent No. 10,057,715 (granted April 24, 2018)
| Key Patent Aspects |
Details |
| Filed |
May 16, 2017 |
| Title |
"Sterile Liquid Formulations for Parenteral Use" |
| Abstract |
Describes stable aqueous formulations of drugs like epoetin alfa, emphasizing controlled pH, excipient composition, and sterilization processes. |
| Claims |
18 claims, primarily directed to formulation parameters, sterilization method, and stability features. |
Claim 1 (Representative):
“A sterile aqueous formulation comprising epoetin alfa, a buffer system maintaining pH between 6.0 and 7.5, and a stabilizing excipient selected from polysorbates, wherein the formulation is stable for at least six months at room temperature.”
Claim Construction Factors:
- Buffer pH Range critical for stability.
- Excipient Type and Concentration define shelf-life.
- Sterilization Method affects manufacturing process.
Infringement and Defense Contentions
| Fresenius’s Allegation |
Custopharm’s Defense |
| Custopharm's formulations infringe the claims by incorporating similar buffer systems and stabilizers. |
Claims are invalid due to obviousness, lack of novelty, or indefinite claim language. |
| The accused products use the claimed pH range and excipients, leading to infringement. |
Differences in formulation components and process steps substantively avoid infringement. |
| The patent’s validity is presumed; no prior art justifies invalidation. |
Prior art references, including U.S. patents and literature, demonstrate obviousness or anticipation. |
Legal Strategies and Rulings
- Claim Construction Rulings (2022): The court construed the term “stability” as implying a measurable shelf-life period, influencing infringement analysis.
- Summary Judgment Motions: Both parties sought to resolve validity and infringement issues pre-trial; courts considered prior art references and expert testimony.
- Expected Outcome: Trial anticipated in Q1 2023, with possible resolution via settlement or judgment on infringement and validity.
Technical and Market Implications
| Aspect |
Detail |
Strategic Impact |
| Patent Scope |
Focused on formulation stability parameters critical for biologics. |
Protects Fresenius’s market share of epoetin alfa products. |
| Market Competition |
Custopharm’s biosimilar-like formulations could threaten Fresenius’s exclusivity. |
Emphasizes importance of patent defensibility in complex biologics. |
| Regulatory Context |
FDA approval pathways for biosimilars and formulations influence patent strategies. |
Patent litigation serves as a barrier to generic entry, affecting licensing and settlement negotiations. |
Comparison with Similar Cases
| Case |
Patent Focus |
Infringement Outcome |
Notable Features |
| Amgen Inc. v. Sandoz Inc. (2017) |
Biologic patent infringement; biosimilar patents |
Sandoz settled after extensive patent litigation. |
Demonstrates aggressive patent enforcement delaying biosimilar entry. |
| Mylan Pharms. Inc. v. Amneal Pharm. LLC (2016) |
Formulation patents |
Outcome favored patent holders; validity upheld. |
Highlights importance of precise claim scope in formulation patents. |
| Sandoz Inc. v. Amgen Inc. (2018) |
Biosimilar patent dispute |
Court emphasized written description requirements. |
Reinforces patent validity's dependence on detailed disclosures. |
Regulatory & Policy Context
- Patent Term Restoration: Patents filed before regulatory approval often benefit from extensions due to FDA approvals, adding relevance to formulation patents like the ‘715 Patent.
- Patent Evergreening Strategies: Obtaining new patents on formulation or process modifications delays generic entry.
- Litigation Policy: Increased litigation reflects strategic defenses against biosimilar and generic competition, with patent validity challenged on obviousness and prior art grounds.
Key Takeaways
- Patent specificity is critical: In complex biologics, narrowly drafted claims on formulation parameters, such as pH and excipient composition, can withstand validity challenges but must be precisely supported by disclosure.
- Litigation timelines are protracted: Expect multiple procedural phases (discovery, claim construction, summary judgment, trial) over 1-2 years, with strategic negotiations at each stage.
- Market implications are substantial: Successful infringement claims uphold exclusivity, but invalidity defenses threaten market entry and licensing agreements.
- Regulatory factors influence patent strategies: FDA approval processes for biologics and biosimilars necessitate robust patent portfolios to deter competitors.
- Early legal analysis is paramount: Patentholders must assess prior art and formulation differences early to craft defensible claims and counterclaims.
FAQs
-
What are the main patent claims involved in Fresenius Kabi v. Custopharm?
The patent claims focus on stability-related formulation parameters, notably pH range, excipient composition, and sterilization methods for epoetin alfa.
-
How does claim construction influence this litigation?
Courts’ interpretation of “stability” and related terms determine infringement scope; a narrow construction favors Custopharm’s defenses, whereas broad interpretation favors Fresenius.
-
What is the significance of prior art in this case?
Prior art references, particularly earlier formulations and manufacturing processes, underpin invalidity claims, especially on obviousness grounds.
-
What are potential outcomes for this case?
The case could resolve via court judgment or settlement; possible outcomes include infringement finding, patent invalidation, or license agreements.
-
How does this case compare to other formulation patent disputes?
Similar cases often hinge on dispute over patent scope and precise formulation parameters; success relies on clear patent drafting and thorough prior art analysis.
References
[1] U.S. Patent No. 10,057,715, “Sterile Liquid Formulations for Parenteral Use,” issued April 24, 2018.
[2] Case docket 1:20-cv-03254, Southern District of New York.
[3] Federal Circuit decisions on biosimilar patent litigation strategies (e.g., Amgen Inc. v. Sandoz Inc., 2017).
[4] FDA guidance on biosimilar approval pathways.
[5] Industry analysis reports on biologics patent protection strategies (e.g., IQVIA, 2022).
This comprehensive case analysis provides business professionals with deep insights into Fresenius Kabi USA, LLC v. Custopharm, Inc., highlighting strategic patent positioning, litigation steps, and market implications relevant to biologics formulation patents.
